Generic Name and Formulations:
Haemophilus b conjugate 7.5mcg (meningococcal protein conjugate 250mcg); per 0.5mL; IM inj.
Merck & Co., Inc.
Indications for PEDVAXHIB:
Immunization of children against H. influenzae type b.
<2 months: not recommended. 2 and 4 months: 0.5mL lM. Children vaccinated (with 2 dose regimen) before 12 months should receive booster at 12 months (but not <2 months after previous shot). Previously unvaccinated children, 15–71 months: 0.5mL lM once.
Immunodeficiency. Delay administration in febrile or active infection. Have epinephrine inj (1:1000) available. Protection begins several days after injection. Pregnancy (Cat. C): not recommended.
Local reactions, fever.
Single-dose vials (w. diluent)—10
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Improving Performance of Everyday Activities Is Critical in Schizophrenia
- Analysis Finds Lithium Maintenance Most Effective as Monotherapy in Bipolar Disorder
- Web-Based Intervention Targets Parental Behaviors That May Affect Adolescent Anxiety, Depression
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Examining Associations Between Diabetes and Effects on Cognition
- Untreated Depression Common in Women of Childbearing Age
- Incidence of Psychiatric Disorders in Rheumatoid Arthritis
- Effect of Antidepressant Class, Dose on Pediatric Anxiety Disorders